Skip to content

Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture

Clinical Trial to Assess the Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Elderly Patients With Spontaneous Hip Fracture

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04183075
Acronym
IRENE
Enrollment
82
Registered
2019-12-03
Start date
2020-09-30
Completion date
2021-05-31
Last updated
2020-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fractures, Malnutrition

Keywords

phase angle, nutritional supplement

Brief summary

Multicenter, prospective, randomized, double-blind, interventional study with a nutritional supplement against placebo in a cohort of patients hospitalized for hip fracture.

Detailed description

Hip fracture is a very prevalent pathology in the elderly population. It is estimated that 35-40% of people over 65 suffer a drop per year, and above 75 years this percentage is even higher, with hip fractures being one of the most serious consequences.With regard to malnutrition, the investigators know that aging carries an increased risk of suffering from decreased appetite and intake and changes in body composition. According to different series, the percentage of malnutrition in patients with hip fracture ranges from 13% to 60%. According to the hospital protocols in Spain in elderly people with spontaneous hip fracture, it is important to perform a nutritional screening during the first 24-48 hours of admission, to evaluate their nutritional status and apply a dietary treatment. The IRENE study aims to determine whether phase angle and reactance, measured by electrical bioimpedance by vector analysis (BIVA) are related to functional recovery in patients with hip fracture.

Interventions

DIETARY_SUPPLEMENTFontActiv Superprotein/Hypercaloric Fiber

The product under study has a liquid presentation, in 200 ml bottles, ready to take

DIETARY_SUPPLEMENTCarbohydrates and C Vitamin

The control product will be prepared with equal presentation and taste as similar as possible tan study product

Sponsors

Laboratorios Ordesa
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 65 years old. * Patients admitted to hospital by spontaneous hip fracture and requiring surgery. * Patients who after hip intervention are included in rehabilitation protocols with outpatient rehabilitation plan. * Patients who agree to participate by signing informed consent or their regular caregivers grant consent.

Exclusion criteria

* Patients who have a hip fracture from high-impact trauma or secondary to bone pathology (such as neoplasm). * Patients with concomitant diseases such as severe hepatic impairment, severe renal impairment, insulin-dependent diabetes melitus and decompensated diabetes mellitus. * Patients who require clinical stabilization before surgery beyond 72 hours. * Patients receiving emergency surgery. * Patients with previous prostheses. * Patients with pacemakers. * Patients who are not likely to complete the follow-up.

Design outcomes

Primary

MeasureTime frameDescription
Compare changes in nutritional status between groups based on phase angleFrom baseline to month 4Compare changes in nutritional status between patients taking nutritional supplement under study and control group based on phase angle measurement (morphological criterion)
Compare changes in nutritional status between groups based on force measurementFrom baseline to month 4Compare changes in nutritional status between patients taking nutritional supplement under study and control group based on force measurement using hand-grip strength ( functional criteria).

Secondary

MeasureTime frameDescription
To compare changes in Mini Nutrition Assessment test for aged peopleFrom baseline to month 4Compare changes in the Mini Nutrition Assessment score between the two study groups. This is a validated test for aged people to assess the nutritional status. Good nutritional state: more than 17points. Bad nutritional state: less than 17 points.
To compare the evolution of the Global Subjective Valuation questionnaireFrom baseline to month 4To compare the evolution of the Global Subjective Valuation between the two study groups. It is a method designed to estimate nutritional status through medical history and physical examination. Each of the sections is valued as mild, moderate or severe, being severe the worst nutritional condition.
Compare changes between groups in the Charlson indexFrom baseline to month 4Charlson index takes into account the number and severity of accompanying diseases to predict the risk of death. Each pathology that patient has, has a number. The higher the number, the worst prediction.
To compare functional recoveryFrom baseline to month 4Compare functional recovery using the Barthel Scale between patients taking nutritional supplement under study and placebo. It is scored on a scale ranging from 0 to 100, with 90 being the maximum score if the patient is in a wheelchair.
Number of participants that die during the studyFrom baseline to month 4Compare the differences in mortality within four months of the start of the study between the two study groups
Compare changes in the ratio RCP/Prealbumin index in the blood analysisFrom baseline to month 4Compare changes in the ratio RCP/Prealbumin index between the two study groups.
Number of participants that have to be readmitted at the hospital.From baseline to month 4Compare the difference in hospital re-admissions between the two study groups.
To compare the morphological recovery by muscle ultrasoundFrom baseline to month 4Compare the morphological recovery valued by muscle ultrasound between patients taking nutritional supplement under study and placebo. Ultrasound performed at baseline and month 4

Countries

Spain

Contacts

Primary ContactRoser De Castellar, MD
RDeCastellar@ordesa.es+34 902105243
Backup ContactSandra Vidal, PhD
svidal@grandfontaine.eu+34 935 516 072

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026